| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d4260a256b5f28ea7d92b4c1f5b921d0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b7f6ea521dadfd94e67aa38307388560
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f7117ccc16362f7996e2f94f30b155be |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70539
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-74 |
| filingDate |
2002-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46d21ad70832e8b76747cadacab9a211
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc1b9ebdd29a60d547943c034384755e |
| publicationDate |
2002-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-02074331-A2 |
| titleOfInvention |
Mutated mhc molecules for use in immune suppression |
| abstract |
The invention provides immunocomplex comprising MHC molecules or functional fragments thereof which are modified so as to prevent binding to co-receptors e.g. CD8 or CD4. The inventors have determined that inability of the MHC complex to bind co-receptor leads to death of the T-cells without delivery of an activation/proliferation signal. By associating the immunocomplex with a specific peptide antigen it is possible to selectively suppress the immune system of a host, i.e. to help prevent tissue rejection or treat autoimmune diseases. For a more universal suppression of the immune system, it is possible to administer the modified MHC complex or fragment/component thereof in the absence of peptide antigen. For example, modified βM complex can be administered. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02102840-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02102840-A3 |
| priorityDate |
2001-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |